Single nucleotide polymorphism- and cell type-dependent gene expression of neuropeptide Y2 receptor

Okada, Mio; Nagai, Masayo; Hamaue, Akiko; Mori, Maiko; Kaji, Hidesuke

doi:10.15761/imm.1000150

Cited by 2 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HepG2 cells were purchased from Health Science Research Resources Bank (Osaka Japan) and cultured in DMEM with 5% fetal bovine serum at 37°C under atmosphere of 5% CO 2 as described previously [11].…”

Section: Cell Culturementioning

confidence: 99%

See 1 more Smart Citation

Blockade of the neuropeptide Y Y2 receptor with the potent antagonist BIIE0246 regulates gene expression levels in the lipid metabolic pathways in human hepatoma cell line HepG2

Kaji¹,

Okada²,

Hamaue³

et al. 2016

Integr Mol Med

View full text Add to dashboard Cite

Neuropeptide Y (NPY) and NPY Y2 receptor (Y2R) is involved in the stress-induced visceral obesity in mice. We have previously reported the association between 5'-flanking region of Y2R gene SNPs and plasma HDL-cholesterol levels in healthy subjects. Plasma HDL-cholesterol levels were significantly different in subjects with each SNPs (rs6857530; GG1.5-fold) 743 entities, and down-regulated (<0.67-fold) 492 entities of 54,675 probe sets. BIIE0246-upregulated genes significantly (P-value<0.001) related to gene ontology (GO) categories of 3 biological processes, 7 cellular components and 1 molecular function. Three biological processes were chylomicron remodeling, negative regulation of cholesterol and sterol transport. BIIE0246-downregulated genes significantly related to GO categories of 44 biological processes, 11 cellular components and 1 molecular function. Furthermore, BIIE0246-downregulated genes were significantly involved in 44 pathways (P<0.01), in which sterol responsive element binding protein signaling were included. BIIE0246-upregulated genes were significantly involved in 22 pathways including vitamin B12/ lipoprotein metabolism (P=0.0048). These results suggest that Y2R blockade might inhibit cholesterol synthesis and raise plasma HDL-cholesterol levels, suggesting a new therapeutic drug for dyslipidemia in subjects with specific Y2R SNPs.

show abstract

Section: Cell Culturementioning

confidence: 99%

“…We have previously reported cell type-and SNP-dependent Y2R gene expression [11]. The luciferase activity was detected in human hepatoma cell line HepG2 when used pGL3-Basic vector inserted with 5'-flanking region of Y2R gene containing rs6857530GG plus rs6857715TT but not with rs6857530 AA plus rs6857715CC.…”

Section: Introductionmentioning

confidence: 99%

Blockade of the neuropeptide Y Y2 receptor with the potent antagonist BIIE0246 regulates gene expression levels in the lipid metabolic pathways in human hepatoma cell line HepG2

Kaji¹,

Okada²,

Hamaue³

et al. 2016

Integr Mol Med

View full text Add to dashboard Cite

show abstract

“…Luciferase activity using gene promoter containing SNPs (G+T) was detectable in HepG2, whereas those containing SNPs (A+C) was detectable in macrophage differentiated from THP-1 cells [4]. Luciferase activity using gene promoter containing neither SNPs (G+T) nor (A+C) was detectable in adipocytes differentiated from 3T3-L1 and human vascular endothelial cells HUEhT-1.…”

mentioning

confidence: 91%

Single nucleotide polymorphism- and cell type-dependent gene expression of neuropeptide Y2 receptor

Cited by 2 publications

References 20 publications

Blockade of the neuropeptide Y Y2 receptor with the potent antagonist BIIE0246 regulates gene expression levels in the lipid metabolic pathways in human hepatoma cell line HepG2

Blockade of the neuropeptide Y Y2 receptor with the potent antagonist BIIE0246 regulates gene expression levels in the lipid metabolic pathways in human hepatoma cell line HepG2

Neuropeptide Y regulates cholesterol metabolism through Y2 receptor in cell- and SNP-dependent manner

Contact Info

Product

Resources

About